Current Development Status of MEK Inhibitors

被引：191

作者：

Cheng, Ying

Tian, Hongqi ^{[1
]}

机构：

[1] Chinese Acad Med Sci, Inst Radiat Med, Tianjin Key Lab Radiat Med & Mol Nucl Med, Tianjin 300192, Peoples R China

来源：

MOLECULES | 2017年 / 22卷 / 10期

关键词：

MEK inhibitors; targeted therapy; combination; approved drug; clinical study; preclinical study; ACTIVATED PROTEIN-KINASE; I DOSE-ESCALATION; PREVIOUSLY TREATED PATIENTS; REFAMETINIB BAY 86-9766; BRAF-MUTANT MELANOMA; CELL LUNG-CANCER; PHASE-I; PIMASERTIB MSC1936369B/AS703026; SELUMETINIB AZD6244; OPEN-LABEL;

D O I：

10.3390/molecules22101551

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical properties and bioactivity characteristics, may provide different options for patients seeking treatment for cancer. Moreover, the combination of the MEK inhibitors with other therapies-such as chemotherapy, targeted therapy, and immunotherapy-may be a promising approach for clinical use.

引用

页数：20

共 97 条

[31]

FANGUSARO JR, 2017, J CLIN ONCOL, V35

[32] A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer [J].

Gandara, David R. ;

Leighl, Natasha ;

Delord, Jean-Pierre ;

Barlesi, Fabrice ;

Bennouna, Jaafar ;

Zalcman, Gerald ;

Infante, Jeffrey R. ;

Reckamp, Karen L. ;

Kelly, Karen ;

Shepherd, Frances A. ;

Mazieres, Julien ;

Janku, Filip ;

Gardner, Olivia S. ;

Mookerjee, Bijoyesh ;

Wu, Yuehui ;

Cox, Donna S. ;

Schramek, Dan ;

Peddareddigari, Vijay ;

Liu, Yuan ;

D'Amelio, Anthony M., Jr. ;

Blumenschein, George, Jr. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (03) :556-566

[33] GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition [J].

Gilmartin, Aidan G. ;

Bleam, Maureen R. ;

Groy, Arthur ;

Moss, Katherine G. ;

Minthorn, Elisabeth A. ;

Kulkarni, Swarupa G. ;

Rominger, Cynthia M. ;

Erskine, Symon ;

Fisher, Kelly E. ;

Yang, Jingsong ;

Zappacosta, Francesca ;

Annan, Roland ;

Sutton, David ;

Laquerre, Sylvie G. .

CLINICAL CANCER RESEARCH, 2011, 17 (05) :989-1000

[34] Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro [J].

Haasbach, Emanuel ;

Hartmayer, Carmen ;

Planz, Oliver .

ANTIVIRAL RESEARCH, 2013, 98 (02) :319-324

[35] The ups and downs of MEK kinase interactions [J].

Hagemann, C ;

Blank, JL .

CELLULAR SIGNALLING, 2001, 13 (12) :863-875

[36] Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors [J].

Han, SL ;

Zhou, V ;

Pan, SF ;

Liu, Y ;

Hornsby, M ;

McMullan, D ;

Klock, HE ;

Haugen, J ;

Lesley, SA ;

Gray, T ;

Caldwell, J ;

Gu, XJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (24) :5467-5473

[37] Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers [J].

Hatzivassiliou, Georgia ;

Haling, Jacob R. ;

Chen, Huifen ;

Song, Kyung ;

Price, Steve ;

Heald, Robert ;

Hewitt, Joanne F. M. ;

Zak, Mark ;

Peck, Ariana ;

Orr, Christine ;

Merchant, Mark ;

Hoeflich, Klaus P. ;

Chan, Jocelyn ;

Luoh, Shiuh-Ming ;

Anderson, Daniel J. ;

Ludlam, Mary J. C. ;

Wiesmann, Christian ;

Ultsch, Mark ;

Friedman, Lori S. ;

Malek, Shiva ;

Belvin, Marcia .

NATURE, 2013, 501 (7466) :232-236

[38] A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer [J].

Haura, Eric B. ;

Ricart, Alejandro D. ;

Larson, Timothy G. ;

Stella, Philip J. ;

Bazhenova, Lyudmila ;

Miller, Vincent A. ;

Cohen, Roger B. ;

Eisenberg, Peter D. ;

Selaru, Paulina ;

Wilner, Keith D. ;

Gadgeel, Shirish M. .

CLINICAL CANCER RESEARCH, 2010, 16 (08) :2450-2457

[39] Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors [J].

Houede, N. ;

Delord, J. P. ;

Awada, A. ;

Lebbe, C. ;

Lesimple, T. ;

Schellens, J. H. M. ;

Rottey, S. ;

Kefford, R. ;

von Richter, O. ;

Raymond, E. .

EUROPEAN JOURNAL OF CANCER, 2012, 48 :184-184

[40] Novel melanoma therapy [J].

Hsueh E.C. ;

Gorantla K.C. .

Experimental Hematology & Oncology, 5 (1)

← 1 2 3 4 5 6 7 8 9 10 →